Vibha Sharma
Her fields of interest include the EU Pharmacovigilance legislation and the EU Paediatrics Regulation on which she has written several exclusive articles from various industry conferences. She has also commissioned some pieces of expert analysis on major developments in the pharma and medtech regulatory arenas.
Before joining Informa, she was principal correspondent with India's national newspaper Hindustan Times, where she reported on health and medical issues, besides several other topics. She has also worked with two other Indian national dailies, The Indian Express and The Asian Age.
Latest From Vibha Sharma
EMA Offers ‘Dynamic Demo’ Of New Clinical Trials Portal
The European Medicines Agency will hold a webinar to explain and demonstrate specific functionalities of the new clinical trials system relevant to clinical trial sponsors.
UK MHRA Explains Procedures For On-Site Inspections In COVID-19 Context
New guidance explains how UK-based sites and organizations can facilitate routine on-site good practice inspections that are due to restart next month.
Canada Asks Insulin Makers To Rectify Inconsistent Product Monographs
A class review of Canadian product monographs for various insulin products has revealed inconsistencies.
Australia Moves To Further Improve Advertising Framework
A review of therapeutic goods advertising reforms that were introduced in Australia in 2018 calls for further changes to support implementation and compliance.
Australia Moves To Further Improve Advertising Framework
A review of therapeutic goods advertising reforms that were introduced in Australia in 2018 calls for further changes to support implementation and compliance.
Companies Get Yet More Time To Assess Nitrosamine Risk In EU
After EU regulators decided that biological medicines should be reviewed for the presence of possible nitrosamine impurities – as is already required for chemical medicines – new deadlines have been agreed on to give companies enough time to comply.